X-DAX
13.820
-1,42%
Dow Jones
31.568
-1,23%
L-TecDAX
3.363
-0,67%
Dollarkurs
1,219
+0,17%
Aktien
News
Forum
Zertifikate
Hebelprodukte
Devisen
Rohstoffe
Fonds
ETFs
Zinsen
Wissen
Depot
Kostenlos
registrieren
Login
Ihre verpassten Browser Pushes der letzten 24 Stunden:
Adhoc-Meldung:
Eine ganz große Überraschung!
Breaking News!!!
Covid-Massentests am größten Flughafen Kanadas!
Alle löschen
Ad hoc-Mitteilungen
Mega-Jackpot-Aktie: Um diese KRYPTO-ÖL-AKTIE wird jetzt sehr schnell ein echter Hype entstehen!
(Anzeige)
•
20:05
CompuGroup Medical
•
18:40
Maternus-Kliniken
•
18:00
NYXOAH S.A.
•
18:00
Wisekey International
•
18:00
ASM International
•
17:30
Cargotec B
•
16:45
Autobank
•
15:30
Suominen
•
15:30
Suominen
•
15:30
Suominen
•
Startseite
Aktien
Nektar Therapeutics Aktie
News
aktualisieren
Nektar Therapeutics News
22.77
22,74
$
-0,13%
-0,03 $
In
: 18,660 € | 20:48:08 Uhr Nasdaq |
Mehr Kurse
»
WKN: 165417
ISIN: US6402681083
US-Symbol:
NKTR
Typ: Aktie
Übersicht
Kurse
Chart
Kennzahlen
News
Forum
Jetzt für 0€ handeln
Watchlist
Depot
Handeln
Alle Nachrichten
dpa-AFX
ARIVA.DE Redaktion
Videos
Unternehmensmeldungen
Ad-hocs
Directors’ Dealings
Analysen
Nektar Therapeutics News
< Zurück
< Zurück
von 27
Weiter >
Weiter >
< Zurück
< Zurück
von 27
Weiter >
Weiter >
15.01.19
- LYNX Analysen
Das sind die stärksten Aktien des Jahres: Nektar Therapeutics
Das Jahr 2019 hat gerade erst begonnen, doch an Bewegung an den Aktienmärkten hat es nicht gemangelt.Blickt man auf Einzeltitel ist die Spanne bereits jetzt enorm. Im S&P500 ...
Mehr »
18.02.21
- PR Newswire
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets PR Newswire
18.02.21
- PR Newswire
Thinking about trading options or stock in Nektar Therapeutics, Sleep Number, General Electric, Twilio, or Spirit Airlines?
Thinking about trading options or stock in Nektar Therapeutics, Sleep Number, General Electric, Twilio, or Spirit Airlines? PR Newswire
17.02.21
- PR Newswire
Thinking about trading options or stock in Vir Biotechnology, Verizon, Nektar Therapeutics, Chevron, or Estee Lauder?
Thinking about trading options or stock in Vir Biotechnology, Verizon, Nektar Therapeutics, Chevron, or Estee Lauder? PR Newswire
17.02.21
- PR Newswire
Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with ...
17.02.21
- PR Newswire
Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer
Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer Nektar to receive up to $150 million in development funding ...
01.02.21
- PR Newswire
Thinking about trading options or stock in Nektar Therapeutics, Pfizer, AstraZeneca, Vir Biotechnology, or Esperion Therapeutics?
Thinking about trading options or stock in Nektar Therapeutics, Pfizer, AstraZeneca, Vir Biotechnology, or Esperion Therapeutics? PR Newswire
31.01.21
- The Motley Fool
3 Aktien, die laut Wall Street 2021 über 50 % steigen werden
Wall-Street-Analysten liegen nicht immer richtig. Das sollte man vorweg ganz klar im Kopf haben. Sie werden jedoch dafür bezahlt, jedes Detail über ein bestimmtes Unternehmen ...
29.01.21
- PR Newswire
Should you invest in Dillard's, Inovio Pharmaceuticals, Eli Lilly, Nektar Therapeutics, or Carnival Corp?
Should you invest in Dillard's, Inovio Pharmaceuticals, Eli Lilly, Nektar Therapeutics, or Carnival Corp? PR Newswire
06.01.21
- PR Newswire
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference PR Newswire
05.01.21
- PR Newswire
Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development
Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development PR Newswire
22.12.20
- PR Newswire
Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million
Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million PR Newswire
15.12.20
- PR Newswire
Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer
Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck ...
07.12.20
- PR Newswire
Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting
Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting PR ...
11.11.20
- PR Newswire
Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting Updated Clinical Data for ...
09.11.20
- PR Newswire
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual ...
05.11.20
- PR Newswire
Nektar Therapeutics Reports Third Quarter 2020 Financial Results
Nektar Therapeutics Reports Third Quarter 2020 Financial Results PR Newswire
04.11.20
- PR Newswire
New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress
New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at 2020 American College of Rheumatology (ACR) Congress PR Newswire
29.10.20
- PR Newswire
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors for 2020 American College of Rheumatology (ACR) Congress PR Newswire
28.10.20
- PR Newswire
Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Third Quarter 2020 on Thursday, November 5, 2020, After Close of U.S.-Based Financial Markets PR Newswire
27.10.20
- PR Newswire
Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19
Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19 Study Designed to Evaluate ...
< Zurück
< Zurück
von 27
Weiter >
Weiter >
Newssuche
Videos
14:41 Uhr
Steuern auf Verluste: "Schlag ins Gesicht der Anleger."
Hunderttausenden Anlegern drohen möglicherweise Steuern auf Verluste. Das liegt am neuen ...
Mehr »
Weitere Videos
NOCH VÖLLIG UNTER DEM RADAR...
BIG GOLD DISCOVERY mit Monster-Bohrloch über 302 Meter – direkt in der Nähe von Kinross Gold und Yamana Gold!
weiterlesen»
Anzeige
wo-site-teaser-box-6420_site-teaser-box_2021-02-25_08%253A00%253A00_2021-02-26_09%253A00%253A59